Literature DB >> 30684199

Factors Affecting Adherence in a Pragmatic Trial of Annual Fecal Immunochemical Testing for Colorectal Cancer.

Carrie M Nielson1, William M Vollmer1, Amanda F Petrik1, Erin M Keast1, Beverly B Green2, Gloria D Coronado3.   

Abstract

BACKGROUND: Colorectal cancer screening by fecal immunochemical test (FIT) reduces the burden of colorectal cancer. However, effectiveness relies on annual adherence, which presents challenges for clinic staff and patients.
OBJECTIVE: Describe FIT return rates and identify factors associated with FIT adherence over 2 years in a mailed FIT outreach program in federally qualified health centers.
DESIGN: Observational study nested in the Strategies and Opportunities to Stop Colon Cancer in Priority Populations (STOP CRC) trial. Five thousand one hundred ninety-five patients had an initial FIT order and were followed for ≥ 2 years (3574 also had a FIT order in the second year). MAIN MEASURES: FIT return percent in each year and patient- and neighborhood-level characteristics associated with FIT adherence. KEY
RESULTS: Overall, the proportion of FIT orders that were completed was 46% in the patients' first year and 41% in the patients' second year. Of the 5195 patients with a FIT order in year 1, 3574 (69%) also had a FIT order in year 2 (71% of year 1 adherers and 67% of year 1 non-adherers, p = 0.009). Among those with a FIT order in the second year, the FIT return rate was about twice as high among those who were adherent in the first year (952/1674, or 57%) as among those who were not (531/1900, or 28%, p < 0.0001). Patient-level characteristics associated with higher odds of FIT return were a history of FIT screening at baseline, age over 65 (vs 50-65), no current tobacco use, recent receipt of a mammogram or flu vaccine, Asian ancestry (compared to non-Hispanic white), and non-English preference. The only neighborhood factor associated with lower FIT return rate was patient's larger residential city size.
CONCLUSION: Our findings can inform the customization of programs to promote FIT return among patients who receive care at federally qualified health centers. TRIAL REGISTRATION: http://www.clinicaltrials.gov.

Entities:  

Keywords:  cancer; colorectal; fecal immunochemical test; screening

Mesh:

Year:  2019        PMID: 30684199      PMCID: PMC6544723          DOI: 10.1007/s11606-018-4820-0

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  43 in total

1.  Receipt of preventive care among adults: insurance status and usual source of care.

Authors:  Jennifer E DeVoe; George E Fryer; Robert Phillips; Larry Green
Journal:  Am J Public Health       Date:  2003-05       Impact factor: 9.308

2.  Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.

Authors:  Kirsten Bibbins-Domingo; David C Grossman; Susan J Curry; Karina W Davidson; John W Epling; Francisco A R García; Matthew W Gillman; Diane M Harper; Alex R Kemper; Alex H Krist; Ann E Kurth; C Seth Landefeld; Carol M Mangione; Douglas K Owens; William R Phillips; Maureen G Phipps; Michael P Pignone; Albert L Siu
Journal:  JAMA       Date:  2016-06-21       Impact factor: 56.272

3.  Predictors of Colorectal Cancer Screening Prior to Implementation of a Large Pragmatic Trial in Federally Qualified Health Centers.

Authors:  Amanda F Petrik; Thuy Le; Erin Keast; Jennifer Rivelli; Keshia Bigler; Beverly Green; William M Vollmer; Gloria Coronado
Journal:  J Community Health       Date:  2018-02

4.  Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality.

Authors:  Ziad F Gellad; Karen M Stechuchak; Deborah A Fisher; Maren K Olsen; Jennifer R McDuffie; Truls Ostbye; William S Yancy
Journal:  Am J Gastroenterol       Date:  2011-02-08       Impact factor: 10.864

5.  Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.

Authors:  Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali
Journal:  Med Care       Date:  2005-11       Impact factor: 2.983

6.  Long-term mortality after screening for colorectal cancer.

Authors:  Aasma Shaukat; Steven J Mongin; Mindy S Geisser; Frank A Lederle; John H Bond; Jack S Mandel; Timothy R Church
Journal:  N Engl J Med       Date:  2013-09-19       Impact factor: 91.245

7.  Continuity of care and cancer screening among health plan enrollees.

Authors:  Joshua J Fenton; Peter Franks; Robert J Reid; Joann G Elmore; Laura-Mae Baldwin
Journal:  Med Care       Date:  2008-01       Impact factor: 2.983

8.  Involvement of previous non-participants cannot fully compensate for lower participation in a second round of FIT-screening.

Authors:  M J Denters; M Deutekom; P M Bossuyt; A F van Rijn; P Fockens; E Dekker
Journal:  Cancer Epidemiol       Date:  2013-02-09       Impact factor: 2.984

9.  An automated intervention with stepped increases in support to increase uptake of colorectal cancer screening: a randomized trial.

Authors:  Beverly B Green; Ching-Yun Wang; Melissa L Anderson; Jessica Chubak; Richard T Meenan; Sally W Vernon; Sharon Fuller
Journal:  Ann Intern Med       Date:  2013-03-05       Impact factor: 25.391

10.  Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.

Authors:  Manuel Zorzi; Cesare Hassan; Giulia Capodaglio; Chiara Fedato; Adriana Montaguti; Anna Turrin; Alberto Rosano; Daniele Monetti; Carmen Stocco; Susanna Baracco; Francesca Russo; Alessandro Repici; Massimo Rugge
Journal:  Gut       Date:  2017-11-03       Impact factor: 23.059

View more
  6 in total

1.  Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention-sponsored Summit.

Authors:  Samir Gupta; Gloria D Coronado; Keith Argenbright; Alison T Brenner; Sheila F Castañeda; Jason A Dominitz; Beverly Green; Rachel B Issaka; Theodore R Levin; Daniel S Reuland; Lisa C Richardson; Douglas J Robertson; Amit G Singal; Michael Pignone
Journal:  CA Cancer J Clin       Date:  2020-06-25       Impact factor: 286.130

Review 2.  Stool-Based Tests for Colorectal Cancer Screening: Performance Benchmarks Lead to High Expected Efficacy.

Authors:  Derek W Ebner; John B Kisiel
Journal:  Curr Gastroenterol Rep       Date:  2020-06-03

3.  What's the "secret sauce"? How implementation variation affects the success of colorectal cancer screening outreach.

Authors:  Jennifer Coury; Edward J Miech; Patricia Styer; Amanda F Petrik; Kelly E Coates; Beverly B Green; Laura-Mae Baldwin; Jean A Shapiro; Gloria D Coronado
Journal:  Implement Sci Commun       Date:  2021-01-11

4.  Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening: Real-world data from a large cohort of older adults.

Authors:  Emily Weiser; Philip D Parks; Rebecca K Swartz; Jack Van Thomme; Philip T Lavin; Paul Limburg; Barry M Berger
Journal:  J Med Screen       Date:  2020-02-13       Impact factor: 2.136

5.  Source matters: a survey of cost variation for fecal immunochemical tests in primary care.

Authors:  Jennifer Coury; Katrina Ramsey; Rose Gunn; Jon Judkins; Melinda Davis
Journal:  BMC Health Serv Res       Date:  2022-02-15       Impact factor: 2.655

Review 6.  Factors promoting breast, cervical and colorectal cancer screenings participation: A systematic review.

Authors:  Federica Vallone; Daniela Lemmo; Maria Luisa Martino; Anna Rosa Donizzetti; Maria Francesca Freda; Francesco Palumbo; Elvira Lorenzo; Angelo D'Argenzio; Daniela Caso
Journal:  Psychooncology       Date:  2022-07-12       Impact factor: 3.955

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.